Identification of Biomarkers Driving Blood Cell Development

Maryam Nazarieh^{1,2,*} and Volkhard Helms^{2,*}

¹Graduate School of Computer Science, Saarland University, Saarbruecken, Germany

²Center for Bioinformatics, Saarland University, Saarbruecken, Germany

*volkhard.helms@bioinformatik.uni-saarland.de,maryam.nazarieh@bioinformatik.uni-saarland.de

October 28, 2021

Abstract

A blood cell lineage consists of several consecutive developmental stages from the pluripotent or multipotent stem cell to a particular stage of terminally differentiated cells. There is considerable interest in identifying the key regulatory genes that govern blood cell development from the gene expression data without considering the underlying network between transcription factors (TFs) and their target genes. In this study, we introduce a novel expression pattern that key regulators expose along the differentiation path. We deploy this pattern to identify the cell-specific key regulators responsible for the development. As proof of concept, we consider this approach to data on six developmental stages from mouse embryonic stem cells to terminally differentiated macrophages.

1 Introduction

The problem of identification of key player genes in gene regulatory networks (GRNs) mainly addressing cell cycle process has been explained in our previous study [1]. In that study, we considered the set of genes that form the minimum dominating set (MDS) and minimum connected dominating set (MCDS) in the largest connected component of the underlying network as the key player genes. In this study, we focus on the identification of key regulatory genes driving blood cell development based on the pattern of gene expression data that they expose for particular stage along the cell development. We got inspired by the pattern of gene expression of the global regulators where the set of global regulators introduced in [2]. In that study, a dynamic core regulatory network is presented by multi-omics analysis where the network consists of 16 TFs that drive cellular differentiation from ESC to terminally differentiated macrophages. Embryonic stem cells (ESCs), Mesoderm (MES), Hemangioblast (HB), Hemogenic endothelium (HE), Hematopoietic progenitor (HP) and Macrophages (MAC) constitute the six consecutive developmental stages. These global regulators which have separate representations for all the developmental stages are connected to each other through a dense network. The network is inferred through a deep muliomics analysis by generating data for RNA-seq, ChIP-seq and DNA-seq measuring global gene expression, chromatin accessibility, histone modifications and transcription factor binding data. Although this network is preserved across all the developmental stages, but the global regulators have separate representations in each stage, e.g., Nanog, Esrrb, Pou5f1 and Sox2 are highly expressed in embryonic stem cell (ESC), where their expression level reach to the least level in the macrophages with gradual decrease along the path. Plotting the expression level of global regulators for all six stages of development with respect to the highest expressed regulators in particular cells inspired us to identify the cellspecific key regulators driving blood cell development from the gene expression data, see Figure 1. The main idea is that a key player associated with a certain differentiated cell has the highest expression value in that cell among all the cells in the lineage. Therefore, the key genes associated with an undifferentiated cell at the top of the lineage have the highest expression level initially, however, the expression level decreases gradually. This pattern of expression looks different for the key players of the cells in the middle stages. In the middle stages, the expression value of a key player gene starts with the least expression value at the top of the hierarchy with a gradual increase along the differentiation path that reaches to the maximum value in the target cell and then decreases gradually till it reaches to the terminally differentiated cells. The genes with the highest expression values at the terminally differentiated cells among all the cells with the gradual increase in expression level from the initial stage are considered as candidates for the key players in those cells.

2 Results

We applied our supervised method to data on six developmental stages from ESCs to terminally differentiated macrophages compiled by (Goode et al. 2016) [2]. The key players in the ESCs have the highest expression level at the initial stage. The expression level decreases gradually when it reaches to the terminally differentiated cells. For other cells along the lineage, the related genes have the least expression value at the ESCs and the highest in the target cells with a gradual decrease till it reaches to the final stage, see Figure 2. This approach identified 332 genes including 22 TFs based on the above-mentioned expression pattern in the ESC stage including Sox2 and Esrrb. Pou5f1 has almost the similar pattern such that it has the highest expression value at the ESC stage, gradually decreases till HE, then less than one unit increase in HP and again reduction till MAC (ESC: 382.02500, MES: 219.5270000, HB: 47.8558000, HE: **0.687413**, HP: **1.19097**, MAC: 0.000000). For Nanog the exception occurred at stage HE such that the expression value at HE is slightly less than HP and MAC (ESC: 58.0737, MES: 34.6255, HB: 5.18978, HE: **0.055367**, HP: **0.0734063**, MAC: 0.0159039). Similarly, 18 TFs were identified for MES and 57, 29, 21 and 10 for HB, HE, HP and MAC among 332, 702, 506, 201 and 309 genes. The set of TFs were extracted from TF-gene interaction database [3].

2.1 Functional annotation

In this work, the biological function of the genes in each stage was evaluated using the enrichment analysis tool provided at the DAVID portal of NIH (version 6.8) based on the functional categories in GO Direct [4]. p-values below the




Figure 1: Expression of the global regulators driving hematopoietic specification for all six stages of blood development from ESCs.




Figure 2: Depiction of the set of TFs for 6 stages of development following the pattern of expression.

threshold 0.05 obtained by the hypergeometric test were adjusted for multiple testing using the Benjamini & Hochberg (BH) method [5].

2.2 Enrichment analysis fo the set of identified TFs

Enrichment analysis for the set of identified TFs in the ESC stage yielded the enriched biological process GO terms and KEGG pathways listed in Table S1. The list includes GO terms such as GO:0048863, GO:0007275, GO:0007492 and GO:0030154 annotated to stem cell differentiation, multicellular organism development, endoderm development and cell differentiation, respectively. Moreover, the set of genes (Onecut1, Esrrb, Id1, Sox2, Zic3) are related to the KEGG pathway: mmu04550 annotated to signaling pathways regulating pluripotency of stem cells. Tables S2-S6 list the enriched GO terms and KEGG pathways for the identified TFs in MES, HB, HE, HP and MAC. The lists include new specialized GO terms in addition to some of the aforementioned terms such as GO:0001569, GO:0045165, GO:0007507 and GO:0030097 annotated to patterning of blood vessels, cell fate commitment, heart development and hemopoiesis, respectively and also a KEGG pathway: mmu05221 annotated to acute myeloid leukemia.

2.3 Enrichment analysis for the set of identified target genes

We inferred the set of target genes for the set of identified TFs from TF-gene interaction database TRRUST [3]. Enrichment analysis for the set of identified target genes in the ESC stage yielded the enriched biological process GO terms and KEGG pathways listed in Table S7. The list includes GO terms such as

GO:0042127, GO:0007275, GO:0048863, GO:0030154, GO:0045165, GO:0048468 and GO:0008283 annotated to regulation of cell proliferation, multicellular organism development, stem cell differentiation, cell differentiation, cell fate commitment, cell development and cell proliferation, respectively. Tables S8-S12 list the enriched GO terms for the target genes in other developmental stages. In addition to common GO terms, distinct GO terms such as GO:0061312 and GO:0016055 with annotations BMP signaling pathway involved in heart development and Wnt signaling pathway are added in MES stage. More specialized GO terms appear in later stages HB and HE and HP such as GO:0001889, GO:0002326, GO:0043583 and GO:0001654 with annotations liver development, B cell lineage commitment, ear development and eye development, respectively.

2.4 Prioritization of the identified TFs

Although the identified TFs in each particular developmental stage follow the aforementioned expression pattern, but they expose different expression levels. Histograms in Figure 3 show the frequency of TFs based on expression level. As the expression level increases, the number of associated TFs reduces.




Figure 3: Histograms of cell-specific TFs in the blood cell lineage.

To prioritize the set of identified TFs, we considered a statistical measure such as quantile. We used 5-quantiles that divides the set of genes into 5 equal groups, see Figure 4. For each cut point, the set of identified genes were considered that are greater or equal the quantile value. Figure 5 shows the number of TFs among the genes. The plots in figure 5 show all the identified TFs initially with constant decrease while increasing the quantile value.




Figure 4: Number of stage-specific genes based on different quantiles.




Figure 5: Number of stage-specific TFs based on different quantiles.

3 Conclusion

We proposed an expression pattern for the identification of biomarkers driving blood cell development. This expression pattern helps to infer the patient-specific biomarkers by considering just the expression level across the cell lineage. No prior knowledge of the regulatory interaction between genes is required to derive the set of biomarkers. We have prioritized the set of identified cell-specific TFs and genes based on the expression pattern. Enrichment analysis suggests that these biomarkers can be potential targets for disease-related biomarkers such as leukaemia.

References

- [1] M. Nazarieh, A. Wiese, T. Will, M. Hamed, and V. Helms. Identification of key player genes in gene regulatory networks. *BMC Systems Biology*, 10(1):88, 2016.
- [2] Debbiek. Goode, Nadine Obier, M.S. Vijayabaskar, Michael Lie-A-Ling, Andrew J. Lilly, Rebecca Hannah, Monika Lichtinger, Kiran Batta, Magdalena Florkowska, Rahima Patel, Mairi Challinor, Kirstie Wallace, Jane Gilmour, Salam A. Assi, Pierre Cauchy, Maarten Hoogenkamp, David R. Westhead, Georges Lacaud, Valerie Kouskoff, Berthold Gttgens, and Constanze Bonifer. Dynamic gene regulatory networks drive hematopoietic specification and differentiation. Developmental Cell, 36(5):572 587, 2016.
- [3] Heonjong Han, Jae-Won Cho, Sangyoung Lee, Ayoung Yun, Hyojin Kim, Dasom Bae, Sunmo Yang, Chan Yeong Kim, Muyoung Lee, Eunbeen Kim, Sungho Lee, Byunghee Kang, Dabin Jeong, Yaeji Kim, Hyeon-Nae Jeon, Haein Jung, Sunhwee Nam, Michael Chung, Jong-Hoon Kim, and Insuk Lee. TRRUST v2: an expanded reference database of human and mouse transcriptional regulatory interactions. Nucleic Acids Research, 46(D1):D380–D386, 10 2017.
- [4] D. W. Huang, B. T. Sherman, and R. A. Lempicki. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. *Nat protocols*, 4:44–57, 2009.
- [5] Y. Benjamini and Y. Hochberg. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J Roy Statist Soc. Series B (Methodological), 57:289–300, 1995.